Enrollment was completed approximately one month ahead of schedule, with results from the study expected to be available by the third quarter of 2008.
This study will evaluate the safety and effectiveness of treatment with Probuphine in reducing opioid dependence over 24 weeks of treatment in approximately 150 patients. This study is part of a registration directed program intended to obtain marketing approval the US and Europe.
Marc Rubin, president and CEO of Titan, said: “We are very pleased with the rapid enrollment of this clinical study. There is a clear desire for additional therapeutic approaches to this disease, and Probuphine has the potential to offer a meaningful treatment alternative.”